PCRX

PCRX

USD

Pacira BioSciences Inc. Common Stock

$24.450+0.100 (0.411%)

Preço em tempo real

Healthcare
Drug Manufacturers - Specialty & Generic
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$24.350

Máximo

$24.590

Mínimo

$23.500

Volume

0.18M

Fundamentos da empresa

Capitalização de mercado

1.1B

Setor

Drug Manufacturers - Specialty & Generic

País

United States

Estatísticas de negociação

Volume médio

0.89M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $11.16Atual $24.450Máximo $29.61

Notícias relacionadas

GlobeNewswire

Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)

PHILADELPHIA, May 26, 2025 (GLOBE NEWSWIRE) -- DoubleVerify Holdings, Inc. (NYSE:DV): If you have held DoubleVerify Holdings, Inc. (NYSE:DV) shares since prior to November 10, 2023, and would like to learn

Ver mais
Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)
GlobeNewswire

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

-- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at

Ver mais
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.